Sublingual buprenorphine/naloxone for chronic pain in at-risk patients

Development and pilot test of a clinical protocol

Andrew Rosenblum, Ricardo A. Cruciani, Eric C Strain, Charles M. Cleland, Herman Joseph, Stephen Magura, Lisa A. Marsch, Laura F. McNicholas, Seddon R. Savage, Arun Sundaram, Russell K. Portenoy

Research output: Contribution to journalArticle

Abstract

Objective: Sublingual buprenorphine/naloxone (Bap/Nx) is approved for addiction treatment and may be useful for pain management, particularly in opioidtreated patients with pain with nonadherence behaviors. The transition of opioidtreated patients with pain to buprenorphine carries the risk of precipitated withdrawal and increased pain. This study convened pain and addiction specialists to develop and pilot a clinical protocol for safe transitioning to Bup/Nx. Design: The protocol was revised three times based on outside expert review and pilot study observations. The pilot was conducted with a prospective cohort of 12 patients with moderate to severe chronic pain, who were receiving long-term opioid therapy with any full μ-agonist drug, and had exhibited one or more aberrant drug-related behaviors. Patients were followed up for 3-6 months with the expectation that they would experience few adverse events (AEs) and report lower pain severity. Results: The three patients on the highest baseline opioid dose (equivalent to 303-450 mg of oral morphine) and the three on the lowest doses (≤20 mg) had early AEs when switched to Bup/Nx and did not complete the trial. Of the remaining six, one withdrew due to AEs; one responded well, then withdrew; and four completed a 3-month trial. A mixed-effects model controlling for dropouts found that average and worst pain significantly decreased after the switch to Bup/Nx (both p <0.01). Conclusion: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing.

Original languageEnglish (US)
Pages (from-to)369-382
Number of pages14
JournalJournal of Opioid Management
Volume8
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Clinical Protocols
Chronic Pain
Pain
Opioid Analgesics
Patient Transfer
Buprenorphine
Pain Management
Naloxone Drug Combination Buprenorphine
Pharmaceutical Preparations
Morphine
Therapeutics

Keywords

  • Buprenotphine
  • Chronic pain
  • Opioid therapy
  • Treatment guidelines
  • Withdrawal

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Anesthesiology and Pain Medicine

Cite this

Sublingual buprenorphine/naloxone for chronic pain in at-risk patients : Development and pilot test of a clinical protocol. / Rosenblum, Andrew; Cruciani, Ricardo A.; Strain, Eric C; Cleland, Charles M.; Joseph, Herman; Magura, Stephen; Marsch, Lisa A.; McNicholas, Laura F.; Savage, Seddon R.; Sundaram, Arun; Portenoy, Russell K.

In: Journal of Opioid Management, Vol. 8, No. 6, 11.2012, p. 369-382.

Research output: Contribution to journalArticle

Rosenblum, A, Cruciani, RA, Strain, EC, Cleland, CM, Joseph, H, Magura, S, Marsch, LA, McNicholas, LF, Savage, SR, Sundaram, A & Portenoy, RK 2012, 'Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol', Journal of Opioid Management, vol. 8, no. 6, pp. 369-382. https://doi.org/10.5055/jom.2012.0137
Rosenblum, Andrew ; Cruciani, Ricardo A. ; Strain, Eric C ; Cleland, Charles M. ; Joseph, Herman ; Magura, Stephen ; Marsch, Lisa A. ; McNicholas, Laura F. ; Savage, Seddon R. ; Sundaram, Arun ; Portenoy, Russell K. / Sublingual buprenorphine/naloxone for chronic pain in at-risk patients : Development and pilot test of a clinical protocol. In: Journal of Opioid Management. 2012 ; Vol. 8, No. 6. pp. 369-382.
@article{11d44b41b91f499fae8d815d11ec626f,
title = "Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol",
abstract = "Objective: Sublingual buprenorphine/naloxone (Bap/Nx) is approved for addiction treatment and may be useful for pain management, particularly in opioidtreated patients with pain with nonadherence behaviors. The transition of opioidtreated patients with pain to buprenorphine carries the risk of precipitated withdrawal and increased pain. This study convened pain and addiction specialists to develop and pilot a clinical protocol for safe transitioning to Bup/Nx. Design: The protocol was revised three times based on outside expert review and pilot study observations. The pilot was conducted with a prospective cohort of 12 patients with moderate to severe chronic pain, who were receiving long-term opioid therapy with any full μ-agonist drug, and had exhibited one or more aberrant drug-related behaviors. Patients were followed up for 3-6 months with the expectation that they would experience few adverse events (AEs) and report lower pain severity. Results: The three patients on the highest baseline opioid dose (equivalent to 303-450 mg of oral morphine) and the three on the lowest doses (≤20 mg) had early AEs when switched to Bup/Nx and did not complete the trial. Of the remaining six, one withdrew due to AEs; one responded well, then withdrew; and four completed a 3-month trial. A mixed-effects model controlling for dropouts found that average and worst pain significantly decreased after the switch to Bup/Nx (both p <0.01). Conclusion: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing.",
keywords = "Buprenotphine, Chronic pain, Opioid therapy, Treatment guidelines, Withdrawal",
author = "Andrew Rosenblum and Cruciani, {Ricardo A.} and Strain, {Eric C} and Cleland, {Charles M.} and Herman Joseph and Stephen Magura and Marsch, {Lisa A.} and McNicholas, {Laura F.} and Savage, {Seddon R.} and Arun Sundaram and Portenoy, {Russell K.}",
year = "2012",
month = "11",
doi = "10.5055/jom.2012.0137",
language = "English (US)",
volume = "8",
pages = "369--382",
journal = "Journal of Opioid Management",
issn = "1551-7489",
publisher = "Weston Medical Publishing",
number = "6",

}

TY - JOUR

T1 - Sublingual buprenorphine/naloxone for chronic pain in at-risk patients

T2 - Development and pilot test of a clinical protocol

AU - Rosenblum, Andrew

AU - Cruciani, Ricardo A.

AU - Strain, Eric C

AU - Cleland, Charles M.

AU - Joseph, Herman

AU - Magura, Stephen

AU - Marsch, Lisa A.

AU - McNicholas, Laura F.

AU - Savage, Seddon R.

AU - Sundaram, Arun

AU - Portenoy, Russell K.

PY - 2012/11

Y1 - 2012/11

N2 - Objective: Sublingual buprenorphine/naloxone (Bap/Nx) is approved for addiction treatment and may be useful for pain management, particularly in opioidtreated patients with pain with nonadherence behaviors. The transition of opioidtreated patients with pain to buprenorphine carries the risk of precipitated withdrawal and increased pain. This study convened pain and addiction specialists to develop and pilot a clinical protocol for safe transitioning to Bup/Nx. Design: The protocol was revised three times based on outside expert review and pilot study observations. The pilot was conducted with a prospective cohort of 12 patients with moderate to severe chronic pain, who were receiving long-term opioid therapy with any full μ-agonist drug, and had exhibited one or more aberrant drug-related behaviors. Patients were followed up for 3-6 months with the expectation that they would experience few adverse events (AEs) and report lower pain severity. Results: The three patients on the highest baseline opioid dose (equivalent to 303-450 mg of oral morphine) and the three on the lowest doses (≤20 mg) had early AEs when switched to Bup/Nx and did not complete the trial. Of the remaining six, one withdrew due to AEs; one responded well, then withdrew; and four completed a 3-month trial. A mixed-effects model controlling for dropouts found that average and worst pain significantly decreased after the switch to Bup/Nx (both p <0.01). Conclusion: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing.

AB - Objective: Sublingual buprenorphine/naloxone (Bap/Nx) is approved for addiction treatment and may be useful for pain management, particularly in opioidtreated patients with pain with nonadherence behaviors. The transition of opioidtreated patients with pain to buprenorphine carries the risk of precipitated withdrawal and increased pain. This study convened pain and addiction specialists to develop and pilot a clinical protocol for safe transitioning to Bup/Nx. Design: The protocol was revised three times based on outside expert review and pilot study observations. The pilot was conducted with a prospective cohort of 12 patients with moderate to severe chronic pain, who were receiving long-term opioid therapy with any full μ-agonist drug, and had exhibited one or more aberrant drug-related behaviors. Patients were followed up for 3-6 months with the expectation that they would experience few adverse events (AEs) and report lower pain severity. Results: The three patients on the highest baseline opioid dose (equivalent to 303-450 mg of oral morphine) and the three on the lowest doses (≤20 mg) had early AEs when switched to Bup/Nx and did not complete the trial. Of the remaining six, one withdrew due to AEs; one responded well, then withdrew; and four completed a 3-month trial. A mixed-effects model controlling for dropouts found that average and worst pain significantly decreased after the switch to Bup/Nx (both p <0.01). Conclusion: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing.

KW - Buprenotphine

KW - Chronic pain

KW - Opioid therapy

KW - Treatment guidelines

KW - Withdrawal

UR - http://www.scopus.com/inward/record.url?scp=84874218968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874218968&partnerID=8YFLogxK

U2 - 10.5055/jom.2012.0137

DO - 10.5055/jom.2012.0137

M3 - Article

VL - 8

SP - 369

EP - 382

JO - Journal of Opioid Management

JF - Journal of Opioid Management

SN - 1551-7489

IS - 6

ER -